<abstract xmlns="http://www.w3.org/1999/xhtml">
<p>Leukemia is a neoplastic disease that affects the proliferation of white blood cells and their progenitors. Folic acid deficiency is well-known as a risk factor for leukemia. Methylenetetrahydrofolate reductase (MTHFR) enzyme functions in the folate metabolism route, DNA synthesis and methylation processes. Numerous research has been conducted to investigate the link between MTHFR and several human illnesses, including cancer, cardiovascular disease, psychiatric disorders and neurological issues. The current study aimed to examine MTHFR levels and gene expression in patients with leukemia. The research was carried out between February and October of 2022. There were 130 subjects in total, 80 with leukemia, 45 with AML (Female = 16, Male = 26) with a mean age of (32.32±2.69), and 35 with ALL (Female = 16, Male = 19) with a mean age of (35.794±0.63). The study included 50 healthy subjects as a healthy control group (Female = 28, Male = 22), with an average age of (41.8±1.57) years. MTHFR and Folic acid were measured using ELISA, while MTHFR mRNA was assessed using qPCR in blood and plasma. Folic acid and MTHFR levels were found to be lower in patients with AML and ALL compared to controls (p &lt;0.01). MTHFR gene expression was found to be downregulated in leukemia patients (p &lt;0.01).</p>
<p>The findings of the study give support for future research into the effect of folic acid level and supplementation on leukemia-associated pathological outcomes. Folic acid deficiency may affect the folate mediate-one carbon metabolism pathway, as evidenced by changes in the expression of the mRNA MTHFR gene. As a result, more research into the effects of folate status and folic acid supplementation on leukemia is needed to investigate potential therapeutic strategies.</p>
</abstract>

Leukemia is a neoplastic disease that affects the proliferation of white blood cells and their progenitors. Folic acid deficiency is well-known as a risk factor for leukemia. Methylenetetrahydrofolate reductase (MTHFR) enzyme functions in the folate metabolism route, DNA synthesis and methylation processes. Numerous research has been conducted to investigate the link between MTHFR and several human illnesses, including cancer, cardiovascular disease, psychiatric disorders and neurological issues. The current study aimed to examine MTHFR levels and gene expression in patients with leukemia. The research was carried out between February and October of 2022. There were 130 subjects in total, 80 with leukemia, 45 with AML (Female = 16, Male = 26) with a mean age of (32.32±2.69), and 35 with ALL (Female = 16, Male = 19) with a mean age of (35.794±0.63). The study included 50 healthy subjects as a healthy control group (Female = 28, Male = 22), with an average age of (41.8±1.57) years. MTHFR and Folic acid were measured using ELISA, while MTHFR mRNA was assessed using qPCR in blood and plasma. Folic acid and MTHFR levels were found to be lower in patients with AML and ALL compared to controls (p <0.01). MTHFR gene expression was found to be downregulated in leukemia patients (p <0.01).
The findings of the study give support for future research into the effect of folic acid level and supplementation on leukemia-associated pathological outcomes. Folic acid deficiency may affect the folate mediate-one carbon metabolism pathway, as evidenced by changes in the expression of the mRNA MTHFR gene. As a result, more research into the effects of folate status and folic acid supplementation on leukemia is needed to investigate potential therapeutic strategies.

Methylenetetrahydrofolate reductase levels and gene expression in leukemia

Department of Chemistry, College of Sciences, University of Al-Qadisiyah

Department of Chemistry, College of Science, University of Kufa

Current Issues in Pharmacy and Medical Sciences

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

{"article-title":"Methylenetetrahydrofolate reductase levels and gene expression in leukemia"}

Leukemia is a neoplastic disease that affects the proliferation of white blood cells and their progenitors. Folic acid deficiency is well-known as a risk...

Methylenetetrahydrofolate reductase levels and gene expression in leukemia

Publié en ligne: 11 avr. 2024

Pages: 7 - 12

Reçu: 15 juil. 2023

Accepté: 09 oct. 2023

DOI: https://doi.org/10.2478/cipms-2024-0002

Mots clés
acute lymphocytic leukemia, acute myeloid leukemia, folic acid (FA), hematopoietic stem cells (HSCs) and methylenetetrahydrofolate reductase (MTHFR).

© 2024 Jinan Thabit et al., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Methylenetetrahydrofolate reductase levels and gene expression in leukemia

Publié en ligne: 11 avr. 2024

Pages: 7 - 12

Reçu: 15 juil. 2023

Accepté: 09 oct. 2023

DOI: https://doi.org/10.2478/cipms-2024-0002

Mots clésacute lymphocytic leukemia, acute myeloid leukemia, folic acid (FA), hematopoietic stem cells (HSCs) and methylenetetrahydrofolate reductase (MTHFR).

© 2024 Jinan Thabit et al., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Mots clés
acute lymphocytic leukemia, acute myeloid leukemia, folic acid (FA), hematopoietic stem cells (HSCs) and methylenetetrahydrofolate reductase (MTHFR).